Spyre Therapeutics Inc. stocks have been trading up by 6.49 percent following highly positive clinical trial advancement news.
Click Here for a Millionaire's POV on Trading SYRE
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Mizuho lifted its price target on Spyre Therapeutics to $120 from $84 after strong SKYLINE Part A data, backing SPY120’s potential for superior clinical remission versus active monotherapy.
- Deutsche Bank boosted its Spyre Therapeutics target to $135 from $115, valuing a third inflammatory bowel disease combo therapy ahead of key IL‑23 data.
- Wall Street now pegs SYRE with an average Buy rating and a roughly $100–$104 price target range, reflecting broad optimism.
- Shares of SYRE slid more than 13% on heavy volume after director Michael Thomas Henderson sold 20,000 shares for about $2M.
- CEO Cameron Turtle and CFO Scott L. Burrows also disclosed sales totaling 30,000 shares, though both still hold sizable positions in SYRE.
Live Update At 16:03:15 EDT: On Friday, July 17, 2026 Spyre Therapeutics Inc. stock [NASDAQ: SYRE] is trending up by 6.49%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
Spyre Therapeutics Inc. is a classic clinical‑stage biotech story: little to no revenue today, but a big balance sheet and an aggressive burn to chase future upside. SYRE’s latest quarterly filing shows cash and short‑term investments of about $741.5M, with $97.2M in cash alone as of 2026/03/31. That gives the company a hefty cash cushion and a current ratio around 9, meaning SYRE has plenty of liquidity relative to near‑term obligations.
At the same time, the income statement is deep in the red. SYRE posted a quarterly net loss of roughly $69M and operating cash burn of about $57M. Management poured around $60.4M into research and development, which is exactly what traders want to see in a high‑growth drug platform, but it also explains the ugly return on equity figures.
More Breaking News
- KLRS Stock Dips As Traders React To Volatile Intraday Spike
- SLS Stock Pops As Price Target Jumps On REGAL Trial Hopes
- EOSE Stock Rallies As Defense Deal And Backlog Fuel Hype
- OPI Jumps After Chapter 11 Restructuring Resets Balance Sheet
On the chart, SYRE has churned between the high‑80s and low‑100s over the past few weeks. The latest close around $100.23 caps a rebound from a dip into the mid‑80s, showing dip buyers are active. Intraday, the 5‑minute tape on the most recent session shows tight trading between roughly $98 and $101, signaling consolidation rather than panic. For traders, SYRE looks like a high‑beta biotech riding news and clinical headlines more than fundamentals.
Why Traders Are Locked In On SYRE
The main reason traders keep SYRE on their screens right now is the series of bullish analyst calls tied directly to Spyre Therapeutics’ inflammatory bowel disease platform. Mizuho raised its price target on Spyre Therapeutics to $120 from $84 after reviewing SKYLINE Part A data for SPY001 and SPY002. The firm highlighted expectations that lead asset SPY120 can deliver better clinical remission than an active monotherapy comparator. In plain English, Street models are starting to assume SYRE’s lead drug may be more effective than existing options.
Deutsche Bank followed with its own upgrade path on SYRE, lifting its target to $135 from $115 and reiterating a Buy rating. The key detail here is not just the higher number; it’s that Deutsche Bank is now explicitly valuing a third combination therapy for inflammatory bowel disease ahead of upcoming IL‑23 data. That tells traders the Street is treating Spyre Therapeutics as a multi‑asset IBD platform, not a single‑drug bet.
Layer on top the FactSet data showing an average target around $100–$104 and a broad Buy consensus, and SYRE starts to look like a name where expectations sit solidly above many recent closes. Even pullbacks into the 80s have bounced, suggesting momentum traders are using weakness to position around these clinical catalysts.
But the story is not clean. Spyre Therapeutics shares slumped more than 13% on heavy volume after filings showed director Michael Thomas Henderson sold 20,000 shares for about $2M. Shortly before and after, CEO Cameron Turtle and CFO Scott L. Burrows each sold 15,000 shares, around $1.32M and $1.3M respectively. While both executives still hold substantial stakes in SYRE, clustered selling often acts as a psychological overhang and a headline trigger for short‑term pressure.
At the same time, SYRE is quietly building out its bench. Spyre Therapeutics granted options on 58,843 shares and 2,134 RSUs to six new non‑executive hires under its inducement plan, with four‑year vesting. That looks like standard biotech scaling: load up on talent ahead of key SPY120 and IL‑23 readouts. BTIG’s read‑through from M&A interest in Apogee Therapeutics—another Paragon spinout—adds a strategic twist. If buyers are sniffing around that ecosystem, traders will logically wonder what Spyre Therapeutics might be worth to a larger pharma down the line.
In short, SYRE is a tug‑of‑war between bullish pipeline expectations and the noise of insider sales and high volatility. That mix is exactly what active traders thrive on.
Conclusion
For active traders, SYRE is shaping up as a textbook biotech momentum play, driven far more by data and expectations than by current earnings. Spyre Therapeutics sits on a strong cash pile, is burning aggressively on R&D, and carries Street targets that stretch well above recent prices. Mizuho’s $120 call and Deutsche Bank’s $135 target frame the upside thesis: SPY120 and the broader IBD combo platform may justify a higher valuation if upcoming readouts cooperate.
On the other side of the tape, clustered insider selling at Spyre Therapeutics has already sparked a double‑digit slide once, reminding traders that sentiment can flip fast. SYRE’s chart over the last few weeks shows sharp swings between the mid‑80s and low‑100s, which is perfect for disciplined day and swing traders but unforgiving for anyone who refuses to manage risk.
The ongoing hiring and equity inducements at Spyre Therapeutics, plus BTIG’s take on ecosystem M&A optionality, add longer‑term intrigue beyond the next press release. But none of that changes the core reality: this is a story stock riding clinical milestones.
As Tim Sykes loves to say, “Volatility is opportunity, but only if you respect risk and cut losses quickly.” SYRE fits that description. And as Tim Bohen, lead trainer with StocksToTrade says, “A consistent trading routine beats sporadic action every time. Show up daily, and you’ll start to see the patterns others miss.” For traders studying Spyre Therapeutics, that means showing up session after session with a structured game plan, reviewing price action and news flow so the repeating setups in SYRE become clearer over time. The job now is to track SPY120 and IL‑23 news, watch how SYRE reacts around the $100 zone, and treat every spike or panic as a potential lesson in how aggressive biotech trading really works. This coverage is for educational and research purposes only and is not investment advice.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.